Orexo (ORX) Q3 2024 earnings summary

Executive summary

• Q3 2024 net revenue was SEK 136.5 million, down 13% year-over-year, mainly due to lower Zubsolv sales, public segment declines, and FX effects; commercial segment showed growth and Zubsolv demand stabilized.

• EBITDA improved to SEK -0.7 million from SEK -9.5 million, but net loss widened to SEK -41.9 million, impacted by higher legal costs and Abstral royalty adjustments.

• FDA approval for OX124 was delayed due to requests for additional technical and stability data; a new human factors study was completed, with resubmission expected mid-2025.

• Legal uncertainties persist, including ongoing DOJ investigation and Sun patent litigation, with at least one resolution expected in 2025.

• Strategic review underway to determine optimal path for R&D in Sweden and commercial operations in the U.S., including potential structural changes.

Financial highlights

• Q3 net revenue: SEK 136.5 million (down from SEK 156.1 million); US Commercial: SEK 131.0 million (down from SEK 140.4 million); HQ & Pipeline: SEK 5.5 million (down from SEK 15.7 million).

• EBITDA for Q3: SEK -0.7 million (improved from SEK -9.5 million); adjusted nine-month EBITDA positive at SEK 20.2 million.

• Gross margin remained high at 86%; operating expenses fell 15% year-over-year, mainly due to lower admin and R&D costs.

• Cash and equivalents at quarter-end were SEK 114.9 million, down from SEK 184.2 million; negative operating cash flow of SEK -13.4 million.

• Net income for Q3: SEK -41.9 million (down from SEK -33.3 million); EPS: SEK -1.21 (down from SEK -0.97).

Outlook and guidance

• 2024 guidance maintained: buprenorphine/naloxone market growth of 2%-5%, Zubsolv net sales in USD in line with 2023, OPEX below SEK 530 million, and positive full-year EBITDA.

• Risks to Zubsolv revenue guidance due to wholesaler inventory adjustments, potential legal settlements, and OX124 NDA resubmission costs.

• Sufficient liquidity for at least the next 12 months; no going concern uncertainty, but equity position remains pressured.

• Expectation of positive inventory effect in Q4, reversing Q3's negative impact.